Efficacy of Topical Azithromycin versus Systemic Doxycycline in Treatment of Meibomian Gland Dysfunction
Table 3
Pain and discomfort, lid margin telangiectasia, conjunctivitis, frothy discharge, meniscus floaters and break-up time test in 1st follow up between studied groups.
Topical azithromycin (n = 28)
Systemic doxycycline (n = 28)
value
Pain and discomfort
Mild
15 (53.57%)
6 (21.43%)
0.024
0.013
Moderate
8 (28.57%)
9 (32.14%)
0.771
Severe
5 (17.86%)
13 (46.43%)
0.022
Lid margin telangiectasia
0 & 1
4 (14.29%)
3 (10.71%)
0.563
2
13 (46.43%)
10 (35.71%)
3
11(39.29%)
15 (53.57%)
Conjunctivitis
+ve
6 (21.43%)
15 (53.57%)
0.013
−ve
22 (78.57%)
13 (46.43%)
Frothy discharge
+ve
7 (25%)
16 (57.14%)
0.028
−ve
21 (75%)
12 (42.86%)
Meniscus floaters
+ve
10(35.71%)
19(67.86%)
0.031
−ve
18(64.29%)
9(32.14%)
Break-up time test (seconds)
7.93 ± 1.94
6.61 ± 2.27
0.023
5–13
3–11
Data are presented as mean ± SD, : significant as value ≤ 0.05.
